---

Highlights of November 2023

 

1.      Eris Lifesciences acquires Biocon Biologics' nephro, derma units for INR366 crore($44 Million)

2.      Zydus Lifesciences Limited and Guardant Health have entered into a co-marketing agreement, in which they will collaboratively promote the Guardant360 collection of liquid and tissue biopsy tests in the territories of India and Nepal.

3.      Lupin, Zydus partners for Co-marketing chronic liver disease treatment in India.

4.      USV and Biogenomics collaboration results in launch of biosimilar insulin aspart INSUQUICK.

5.      Torrent Pharma inks licensing pact with Zydus for liver disease drug.

6.      Mylab collaborates with Ekincare to promote NASOVAC-S4 influenza nasal vaccine.

7.      Eli Lilly extends tender offer to buy Point Biopharma after low participation.

8.      Vironova BioAnalytics has announced its acquisition led by QuatreLab with the participation of Accord Investment Partners and Venture Targeter AB.

9.      Chiesi in-licenses DPP1 inhibitor from Haisco Pharma.

10.  Advanz Pharma gains global rights to Androcur from Bayer.

11.  AstraZeneca and Eccogene have entered into an exclusive license agreement for an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA).

 

Highlights at Aagami:

1.      Aagami achieved a successful conclusion to its participation in Bio-Europe 2023 held in Munich, Germany, from November 6 to 8, led by Vice-President Godwyn Francis. The company conducted over 35 strategic one-on-one meetings with worldwide decision makers during the conference.

 

2.      Aagami is poised to uphold its tradition of participating in JP Morgan Healthcare week including Biotech Showcase 2024 in San Francisco (Jan 8-10, 2024). The company will be represented by its CEO, Dinesh Jain, who will showcase the company and its clients.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.    Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®. Other high potential Biosimilars are also available for multiple regions.
2.    Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).
3. Seeking Licensing/Co-development:  A phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity from Japanese client.
4. Seeking Licensing/Co-development: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief.
5. For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drugcandidates, IP etc.- for Next-generation biologics and substantial returns.
2.  Asset, Data package and IP Sale -  NCE Oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia (Phase 1 ready). Strong Preclinical Package.
3. Asset sale –US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking US$15 million: Nose to brain delivery (intra-nasal and bypassing the blood brain barrier) technology development company targeting orphan diseases such as FrontoTemporal Dementia (FTD), Alzheimer’s disease, Dementia with Lewy Bodies and Parkinson's disease.
2. Invest in the future with Integrated Autoimmune Company: Seeking $15 million for Go to market campaign for first product and key milestones.
3. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
4. Seeking US$5 million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.